MCM3 and breast carcinoma: The MCM3 level was examined by immunohistochemistry in the Stockholm Tamoxifen (STO-3) trial from the Stockholm Breast Cancer Study Group randomizing postmenopausal lymph node-negative breast cancer patients to receive adjuvant tamoxifen versus not15.